Novo Nordisk has announced the filing of 14 new lawsuits against the sale of unapproved compounded drugs claiming to contain ...

Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout that ...

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit today, but rising competition is ...

Novo Nordisk (NVO) said Wednesday it will cut costs as it faces increasing competition from Eli Lilly (LLY) and generic ...

Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...

Eurozone retail sales are expected to rebound 0.4% on a monthly basis in June from the previous month’s drop of 0.7%, with ...

Novo Nordisk, the maker of Wegovy, plans to cut costs and refocus commercially after a $95 billion stock loss. The company's market cap has dropped to around $212 billion.

Glencore Earnings Fall on Lower Coal Prices, Copper Production Challenges The commodities giant said the results reflect lower coal prices and a drop in copper production following operational ...

Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

Semaglutide--which is marketed as Wegovy for weight-loss and Ozempic for diabetes--had been in short supply as the company raced to increase production and meet surging demand. But the drug came off ...

Danish pharmaceutical firm Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, announced Wednesday a 32 percent increase in net profit for the second ...